Technology
Health
Biotechnology

Immutep

$1.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-2.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Immutep and other stocks, options, ETFs, and crypto commission-free!

About

Immutep Limited American Depositary Shares, also called Immutep, is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. Read More The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Employees
Headquarters
Sydney, New South Wales (NSW)
Founded
1987
Market Cap
65.55M
Price-Earnings Ratio
Dividend Yield
Average Volume
135.66K
High Today
$2.05
Low Today
$1.92
Open Price
$2.03
Volume
18.99K
52 Week High
$4.21
52 Week Low
$1.77

Collections

Technology
Health
Biotechnology
Cancer Prevention
Research And Development
Medical

News

Yahoo FinanceMay 10

Immutep Announces Upcoming Industry Conference Participation

SYDNEY, Australia, May 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces participation at upcoming industry conferences.

37
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.